Received Jun 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 1 | — | — |
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 2 | — | — |
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 3 | — | — |
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 4 | — | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 1 | — | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 2 | — | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 3 | — | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 4 | — | — |
the patient inadvertently received a 4th dose of the ROTATEQ vaccine/ received an extra dose of VAXELIS; no adverse reaction to extra dose; This spontaneous report was received from a physician and refers to a 15-month-old patient of unknown gender. The patient's medical history, concurrent conditions, previous drugs reactions or allergies were not provided. Concomitant medications included Pneumococcal vaccine conj 20v (CRM197) (PREVNAR 20). On 04-JUN-2024, 05-AUG-2024, 16-SEP-2024, the patient was vaccinated with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus (VAXELIS), dose number 1-2 and 3, (doses descriptions, lot #s and expiration date were not reported), then on 08-OCT-2024, at their 6 month well check, the patient had inadvertently received an extra dose (dose number 4) of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus (VAXELIS) (dose description, lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient was vaccinated with Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) dose number 1-2 and 3 (doses description, route of administrations, lot #s and expiration dates were not reported), then, 3 weeks after completing the 3-dose series for the vaccine, on an unknown date, the patient inadvertently received a 4th dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) (dose description, route of administration, lot # and expiration date were not reported) for prophylaxis. The patient experienced no adverse reaction to extra dose.
PREVNAR 20